| Gene symbol | BCL2 | Synonyms | Bcl-2, PPP1R50 | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q21.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | BCL2 apoptosis regulator | ||||
| GTO ID | GTC1217 |
| Trial ID | NCT00078234 |
| Disease | Chronic Lymphocytic Leukemia |
| Altered gene | Bcl-2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Genasense|G3139|oblimersen sodium |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Pilot Study of Genasense (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia |
| Year | 2004 |
| Country | United States |
| Company sponsor | Genta Incorporated |
| Other ID(s) | GL217 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||